A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2016

Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
DRUG

PledOx (2 µmol/kg)

PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.

DRUG

PledOx (5 µmol/kg)

PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles

DRUG

PledOx (10 µmol/kg)

PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles

DRUG

Placebo (0,9% NaCl)

Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.

Trial Locations (33)

179

S. Khechinashvili University Hospital, Tbilisi

1303

"MHAT Serdika EOOD, Department of Medical Oncology", Sofia

1527

"UMHAT Tzaritza Joanna-ISUL EAD, Clinic of Medical Oncology", Sofia

1756

SHATO EAD, Sofia, Clinic of Chemotherapy, Sofia

4004

Complex Oncology Center-Plovdiv EOOD, Department of Medical Oncology and oncology diseases in gastroenterology, Plovdiv

5000

Odense Universitetshospital, Klinisk Forsknings Enhed, Onkologisk Afdelig R, Odense

6000

LTD Clinic Medina, Batumi

9000

Aalborg University Hospital, Dept of Oncology, Clinical Research Unit, Aalborg

9700

Complex Oncology Center-Shumen EOOD, Department of Medical Oncology, Shumen

11000

Institute for Oncology and Radiology of Serbia, Clinic for Medical Oncology, Belgrade

Military Medical Academy, Gastroenterology department, Belgrade

11080

Clinical Hospital Center Zemun, Insitute for Oncology, Belgrade

20817

Center for Cancer and Blood Disorders, Bethesda

34000

Clinical Center Kragujevac, Center for Oncology, Kragujevac

37421

Associates in Oncology & Hematology, Chattanooga

37660

Wellmont Medical Associates Oncology and Hematology, Kingsport

41685

Sahlgrenska/Östra sjukhuset, Gothenburg

42283

HELIOS Klinikum Wuppertal, Klinik für Hämatologie und Onkologie, Wuppertal

44791

St. Josef-Hospital -Universitätsklinik Ruhr-Universität Bochum, Leitende Ärztin der Abt. für Hämatologie und Onkologie, Medizinische Klinik I, Bochum

78229

The University of Texas, Health Science Center at San Antonio, San Antonio

80187

Gävle sjukhus, Oncology unit, Gävle

98101

Benaroya Research Institute @ Virginia Mason, Seattle

92093-0698

Moores UCSD Cancer Center, La Jolla

0112

Resaerch Institte of Clinical Medicine, Tbilisi

0131

"JSC Neo Medi", Tbilisi

0144

"LTD High Technology Medical Center University Clinic", Tbilisi

01307

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie -Onkologie, Dresden

3814-501

Centro Hospitalar do Baixo Vouga, E.P.E. (Hospital Infante D. Pedro), Oncologia Médica, Aveiro

4710-243

Hospital de Braga, Oncologia Médica, Braga

4200-072

Instituto Português de Oncologia do Porto, Francisco Gentil, E.P.E., Oncologia Médica, Porto

SE-581 85

Universitetssjukhuset i Linköping, Linköping

Unknown

Karolinska Sjukhuset, Stockholm

Akademiska Sjukhuset, Uppsala

Sponsors
All Listed Sponsors
collaborator

Pharma Consulting Group AB

INDUSTRY

lead

Egetis Therapeutics

INDUSTRY

NCT01619423 - A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter